MSD is looking for a digital health solution to empower oncologists by keeping them updated in their field

MSD Lebanon is looking for an external partner to co-create a digital solution that helps oncologists to stay updated with relevant clinical content about cancer. The solution should consider several channels (web, app, email newsletter, social media, etc) and adapt to the preferences to each user, so they are motivated to access the content regularly over time.

As a leading pharmaceutical company, MSD is aware of the need to incorporate open Innovation for better healthcare. The best ideas may not always pop up where challenges are identified. That is why MSD wants to support and partner with external talent to collaboratively develop competitive solutions following a win-win approach.

The Lebanon-College Challenge: Empowering oncologists to save lives

Lebanese oncologists face challenges to stay updated with their practice, mainly due to time constraints. The vast amount of data that is being published in the field, and their clinical and academic responsibilities, are the main reasons for these time limitations.

MSD Lebanon aims to enter into a co-creation process with an external partner that provides the service that includes the use of a digital solution that helps oncologists to stay updated with relevant clinical content about cancer updates. The applicant must be able to provide both the content and the technological platform to deliver it to the Lebanese doctors.

Expected functionality and characteristics: The applicant must be able to manage the whole life-cycle of the content - identification, selection, tagging, uploading. Besides, the digital solution must be: user-friendly, trustable, multi-channel, multi-content, customizable, adherent, measurable, restricted to Lebanese oncologists, provide printed copies of content, comply with security and privacy.

The schedule

The process is done in five steps:
1. Solutions submitted before 21st December 2018 are reviewed by the MSD team.
2. Up to four finalists will be announced on 21st January 2019.
3. Finalists receive mentorship to improve their initial proposal.
4. Finalists pitch their proposal at the Selection Event in Beirut on 5th March 2019.
5. Winning proposal will be co-created and rolled-out in the local market with MSD team support.

The prizes

The winner will receive the following:
  • Up to $20,000 to pilot their solution in the challenge-related local market (Lebanon).
  • Support from MSD local team to connect with the local ecosystem (eg. medical professional associations), deal with potential regulatory issues and disseminate leveraging MSD local channels. It will also contribute with expertise and business know-how.
  • If the launch is a success after 12 months, its outcomes will be globally shared within MSD to investigate further implementation beyond the initial market.

Each finalist will receive €400 to cover travel expenses. It is compulsory to physically attend the event to become a winner (no remote presentations).

Who can apply? Any company that is incorporated in any country. Consortia are permitted. Any technology is welcome with the exception of chatbots. The working language will be English.

For detailed information about the initiative including challenges and process, please visit:
http://www.msdinnovationfactory.com

About the MSD Innovation Factory and MEA Region

Since 2016 the MSD Innovation Factory has been established as an open innovation vehicle for the MEA Region with the main objective of finding co-creation opportunities with external partners to deliver sustainable solutions for our patients and customers.

With a footprint that spans across 2 continents and serving a population of close to 1.7 billion people, MEA is one of the most diverse regions within MSD. Our region is a true melting pot, possessing a rich mix of cultures, ethnicities and backgrounds that are fundamental to our company's success. As we aspire to improve health and wellness across MEA, we apply the combined knowledge, skills and experiences of thousands of employees in the Human Health, Animal Health, Manufacturing and Research divisions.

Our researchers are at the forefront of exploring new ways to address health challenges, with clinical trials running in several countries across the region. High disease burdens across the region for Cancer, Hepatitis C and Diabetes among many others, keep us conscious of our responsibility, and committed to our mission to ensure that the medicines and vaccines we invent will lead to better health for society for generations to come.

Most Popular Now

Amgen and Allergan's MVASI™ (bevacizumab-awwb) and…

Amgen (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) announced that MVASI™ (bevacizumab-awwb), a biosimilar to Avastin® (bevacizumab), and KANJINTITM (trastuzumab-anns), a bio...

Compound found in red wine opens door for new trea…

Like to unwind with a glass of red wine after a stressful day? Don't give alcohol all the credit. New research has revealed that the plant compound resveratrol, which is ...

HIV vaccine nears clinical trial following new fin…

A promising vaccine that clears an HIV-like virus from monkeys is closer to human testing after a new, weakened version of the vaccine has been shown to provide similar p...

Mylan and Upjohn, a division of Pfizer, to combine…

HERTFORDSHIRE, England & PITTSBURGH & Mylan N.V. (Nasdaq: MYL) and Pfizer Inc. (NYSE: PFE) today announced a definitive agreement to combine Mylan with Upjohn, Pfizer's o...

Leading oncologists and nutritionists pinpoint are…

An international collaborative led by Ludwig Cancer Research and Cancer Research UK has identified key areas that are central to uncovering the complex relationship betwe...

Closing the door: breaking new ground related to a…

In order to sustain fast growth, cancer cells need to take up nutrients at a faster rate than healthy cells. The human glutamine transporter ASCT2 allows the amino acid g...

FDA approves first generics of Lyrica

On July 19, the U.S. Food and Drug Administration approved multiple applications for first generics of Lyrica (pregabalin) for the management of neuropathic pain associat...

Roche and Spark Therapeutics, Inc. announce extens…

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) ("Spark") announced that Roche has extended the offering period of its previously announced...

FDA approves first treatment for severe hypoglycem…

The U.S. Food and Drug Administration today approved Baqsimi nasal powder, the first glucagon therapy approved for the emergency treatment of severe hypoglycemia that c...

Rye is healthy, thanks to an interplay of microbes

Eating rye comes with a variety of health benefits. A new study from the University of Eastern Finland now shows that both lactic acid bacteria and gut bacteria contribut...

GSK completes transaction with Pfizer to form new …

The Joint Venture brings together two highly complementary portfolios of trusted consumer health brands, including GSK's Sensodyne, Voltaren and Panadol and Pfizer's Advi...

Eating more plant-based foods may be linked to bet…

Eating mostly plant-based foods and fewer animal-based foods may be linked to better heart health and a lower risk of dying from a heart attack, stroke or other cardiovas...